RxDoctor Payments Data

Mark Miller, MD

Interventional Cardiology · Anaheim, CANPI 1073575353

Payments from drug & device makers

$31,927in general payments, 2019–2025

Across 429 payments — averaging $74.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$11K
  • AstraZeneca$7K
  • Bayer$6K
  • Johnson & Johnson$1000
  • Pfizer$690
  • Edwards Lifesciences$688
  • plus $6K from 31 others

What the payments were for

  • Speaking & faculty fees$21,62668%
  • Travel & lodging$250%
  • Food & beverage$10,09832%
  • Education$1791%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,927 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,435
Medicare patients
11
Services billed
18

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban88$93,552
EntrestoSacubitril/Valsartan70$86,141
XareltoRivaroxaban63$67,304
Ezetimibe68$1,921
Digoxin62$1,378
Ranolazine ErRanolazine12$1,294
Rosuvastatin Calcium65$1,147
Flecainide Acetate18$959
Torsemide40$625
Atorvastatin Calcium76$577
Hydralazine Hcl12$520
Metoprolol Succinate35$509
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$508
Valsartan17$438
Losartan Potassium35$417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$690$93,55288 claims
NovartisEntresto$10,798$86,14170 claims
Johnson & JohnsonXarelto$1,000$67,30463 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →